arrow
M

Michael R. Bishop

university of chicago
H指数:38
被引数:6,763

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Favorable survival for older adults treated with Axi-cel and Tisa-cel CD19 CAR-T therapy for relapsed/refractory DLBCL: a U.S. multicenter comparative analysis

老年复发性/难治性弥漫大B细胞淋巴瘤患者接受Axi-cel和Tisa-cel CD19 CAR-T治疗的良好生存结果:一项美国多中心比较分析

2026-10-190
PRE
Late cytopenia after CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a Cell Therapy Consortium analysis

CD19嵌合抗原受体T细胞疗法后出现的迟发性血细胞减少:细胞治疗联盟的分析

2026-06-260
OA
Autologous T Cell Antigen Coupler Targeting HER2 (TAC01-HER2) in Advanced or Metastatic Solid Tumors

自体T细胞抗原偶联物靶向HER2(TAC01-HER2)在晚期或转移性实体瘤中的应用

2026-05-220
PRE
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma

CTX110作为异基因CD19靶向CAR-T疗法在复发/难治性B细胞非霍奇金淋巴瘤中的安全性与有效性

2026-05-070
OAAI
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia

社会决定因素对成人复发/难治性B细胞急性淋巴细胞白血病患者brexucabtagene autoleucel治疗结局的影响

2025-08-230
OAAI
Usefulness and Limitations of Polymerase Chain Reaction (PCR) for the Diagnosis and Management of Toxoplasmosis Following Allogeneic Hematopoietic Cell Transplant: Single-center Experience With 31 Patients Over 16 Years

聚合酶链式反应(PCR)在异基因造血细胞移植后弓形虫病诊断与管理中的有效性与局限性:单中心16年经验,涉及31例患者

2025-08-050
OAAI
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL

评估接受tisagenlecleucel治疗的复发/难治性B-ALL和DLBCL患者体内CAR转座子水平的评价

2025-06-260
OAAI
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

接受brexucabtagene autoleucel治疗的复发或难治性B细胞急性淋巴细胞白血病成年患者的三年分析(ZUMA-3)

LEUKEMIA
IF13.4
2025-03-191
OAAI
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia

成人b细胞急性淋巴细胞白血病的Obecabtagene自体白血病

2024-12-120
PRE
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
2024-12-102
OAAI
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

确定最佳氟达拉滨暴露以改善axi-cel治疗侵袭性b细胞非霍奇金淋巴瘤后的结果

2023-09-1812
OAAI
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions
2023-08-1120
OAAI